Tumor Infiltrating Lymphocytes Market

Tumor Infiltrating Lymphocytes Market: Introduction

• Advanced therapy medical products (ATMPs), such as tumor infiltrating lymphocytes therapy, exhibit significant potential for the treatment of advanced melanoma in clinical environments. ATMPs, in general, are reckoned as personalized approach for cancer treatment. Tumor infiltrating lymphocytes (TILs) are an important prognostic factor in melanoma and are associated with better outcomes in epithelial ovarian cancer.

Key Drivers and Opportunities of Global Tumor Infiltrating Lymphocytes Market

• Increase in number of patients with cancer drives the demand for tumor infiltrating lymphocytes therapy, which in turn fuels the growth of the global market. According to the American Society of Clinical Oncology (ASCO), melanoma accounts for 1% of all skin cancer cases diagnosed in the U.S., and causes most of the deaths from skin cancer
• Moreover, promising approach to treat various types of cancer and rise in awareness about the success outcome of infiltration of tumor by immune cells for various malignancies are projected to boost the growth of the global market.
• Increase in focus on developing tumor infiltrating lymphocytes due to several benefits contributes to the growth of global tumor infiltrating lymphocytes market. The National Institute of Cancer has been enrolling cancer patients, and the subset of patients with metastatic melanoma have shown impressive response to tumor infiltrating lymphocytes therapy over time. The efficacy of the treatment has been strengthened with impressive responses, with disease recurrence experienced by only two responders. Additionally, rise in popularity of the next generation technology propels the global market.
• However, high cost and time consuming manufacturing process are likely to hamper the growth of the global tumor infiltrating lymphocytes market

North America to Dominate the Global Tumor Infiltrating Lymphocytes Market

• In terms of region, the global tumor infiltrating lymphocytes market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global tumor infiltrating lymphocytes market during the forecast period. New product launches, presence of key players with strong focus on research & development, and early adoption of advanced technologies are anticipated to drive the tumor infiltrating lymphocytes market in the region during the forecast period.
• The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period owing to surge in number of patients with cancer and government initiatives to increase the health care infrastructure

Key Players Operating in Global Tumor Infiltrating Lymphocytes Market

The global tumor infiltrating lymphocytes market is fragmented due to the presence of large number of international as well as local players. These players hold major share in their respective regions. Demand for tumor infiltrating lymphocytes products has increased in emerging as well as developed markets owing to rise in awareness about technological advanced products. Growth strategies adopted by leading players are likely to drive the global market.

Key players operating in the global tumor infiltrating lymphocytes market are:

• TILT Biotherapeutics Ltd.
• Bellicum Phamaceuticals, Inc.
• Iovance Biotherapeutics, Inc.
• Pfizer, Inc.
• Precision Biosciences
• Unum Therapeutics
• Fate Therapeutics
• Merck KGaA

Global Tumor Infiltrating Lymphocytes Market: Research Scope

Global Tumor Infiltrating Lymphocytes Market, by Application

• Melanoma
• Cervical Cancer
• Ovarian Cancer
• Others

Global Tumor Infiltrating Lymphocytes Market, by Sub-type

• CD3
• CD8
• CD16
• CD56
• CD4
• CD57

Global Tumor Infiltrating Lymphocytes Market, by End-user

• Hospital & Specialty Clinics
• Research Institutes
• Others

Global Tumor Infiltrating Lymphocytes Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa